For the replacement of current HIV-1 medicines in adults who meet certain requirements. See Full Indication.
Hello, Undetectable you.
Meet JULUCA.
JULUCA is a once-daily, complete HIV-1
regimen that may help keep you undetectable* with
just 2 medicines in 1 small pill.†
*Undetectable means keeping the amount of HIV-1 in your blood at very low levels (less than 50 copies per mL).
†You must be undetectable for at least 6 months before starting JULUCA.
Now that you’re
undetectable,* have you
thought
about
what’s next?
There are many HIV treatment options available. Do you know how many medicines are in your HIV regimen?
Ask your doctor if JULUCA could be a next step for you.
Taking JULUCA.
Understanding the "how" and "when" of taking JULUCA is important. Be sure to keep these considerations in mind:
Take JULUCA every day with a meal — exactly as your doctor tells you.
Taking JULUCA with a meal is important to help get the right amount of medicine in your body. A protein drink alone does not replace a meal.
Take JULUCA around the same time every day (or night).
Choose whatever time works best with your daily routine.
Take JULUCA as a replacement for your current HIV regimen.
JULUCA is a complete HIV-1 regimen, so it isn’t an addition to your current treatment, and it shouldn’t be taken with any other HIV-1 medicines.
Take JULUCA exactly as prescribed.
Do not miss a dose, change your dose, or stop taking JULUCA without talking to your doctor. Stay under a healthcare provider’s care when taking JULUCA.
Some prescription and over-the-counter medicines interact with JULUCA and need to be taken at a different time from when you take JULUCA. See the Risks & Side Effects page for more information.
Remember, it’s important to keep your overall health in mind when considering HIV treatment options. Your doctor is a good source of information. Be sure to talk with him or her if you have questions.
Clinical trials.
This study included 2 groups of patients, those who took JULUCA for 148 weeks and those who switched from their current stable regimen|| to JULUCA at week 52.
Patients who entered these studies were undetectable§ and on their current regimen for at least 6 months. They could not participate if they had liver problems, active hepatitis B, were likely to need treatment for hepatitis C during the trials, had failed a prior HIV treatment, or if they had suspected resistance to the components of JULUCA (dolutegravir or rilpivirine).
43 years was the median age of participants. |
28% of participants were at least 50 years of age. |
22% of participants were female. |
The results are in.
In these studies, most people stayed undetectable when they switched to JULUCA.¶
AT 48 WEEKS
1 pill with 2 medicines was as effective at keeping people undetectable¶ as their previous 3- or 4-drug regimens.||
95% of people who switched to JULUCA stayed undetectable§
95% of people who stayed on their current HIV regimen stayed undetectable§
AT 148 WEEKS
84% of people who took JULUCA from the beginning of the study stayed undetectable§
90% of people who switched to JULUCA at Week 52 stayed undetectable§
‡Both patients and their healthcare providers knew which medicines patients were taking.
§Undetectable means the amount of HIV-1 in the patients' blood was at very low levels (less than 50 copies per mL).
||Regimens contained 2 nucleoside reverse transcriptase inhibitors (NRTIs) plus either an integrase strand transfer inhibitor (INSTI), a non-nucleoside reverse transcriptase inhibitor (NNRTI), or a protease inhibitor (PI).
¶Your results may vary.
What can you expect?
You may experience some side effects when switching medications.
Here are the side effects reported in ≥2% of participants¶:
SWITCHED TO JULUCA AT THE START OF THE TRIALS
| Taking JULUCA | ||
| Common Side Effects |
Weeks 1-48 |
Weeks 1-148 |
|---|---|---|
| Diarrhea |
2% | 1% |
| Headache |
2% | 2% |
| Nausea |
1% | 2% |
| Insomnia | <1% | 1% |
CONTINUED CURRENT HIV REGIMEN AT THE START OF THE TRIALS
| Taking Current HIV Regimen |
Switched to JULUCA | |
| Common Side Effects |
Weeks 1-48 |
Weeks 52-148 |
|---|---|---|
| Diarrhea |
<1% | 1% |
| Headache | 0% | 2% |
| Nausea | 0% | 1% |
| Insomnia | <1% | 2% |
SWITCHED TO JULUCA AT THE START OF THE TRIALS
| Taking JULUCA | ||
| Discontinuation |
Weeks 1-48 |
Weeks 1-148 |
|---|---|---|
| People who left the study due to adverse events |
4% | 8% |
CONTINUED CURRENT HIV REGIMEN AT THE START OF THE TRIALS
| Taking Current HIV Regimen |
Switched to JULUCA | |
| Discontinuation |
Weeks 1-48 |
Weeks 52-148 |
|---|---|---|
| People who left the study due to adverse events |
<1% | 4% |
Of the people who took JULUCA from Week 1 and left the study due to adverse events, the most common type of adverse event leading to discontinuation was psychiatric disorders (3%).
¶Your results may vary.
I went through a lot to get to undetectable,
and reaching it was
one of the
greatest
achievements of my life.
Alex Undetectable since 2011
Sign up to receive more information about JULUCA
and get this free guide, Living Healthy With HIV.
Learn how to build on treatment success with tips for improving your overall health and well-being.
